[ad_1]
The Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) works to stabilize the production and distribution of medicines.
The measures adopted to ensure the import of raw materials and increase production levels have reduced the remaining products to 48, says today the information published in the newspaper Granma .
Rita García Almaguer, director of operations and technology at BioCubaFarma, said that the biggest effort is focused on priority or controlled drugs, he confirmed that of the 761 medicines that make up the base table, 482 are produced by the biotechnology and pharmaceutical industries, representing approximately 82% of what is marketed in the retailer's network.
He stated that the main causes that affect the production of drugs are the lack of financing or portuno to acquire raw materials, packaging and other inputs, as well as internal deficiencies.
This is a very specific industry, said Rita García, in which, if a supplier stops offering a certain product, looking for another implies
He also stressed the influence of the blockade American, which entails high costs for not using the dollar in transactions, difficulties in banks and the obligation to use third countries.
the industry is making a considerable effort and is also working to improve the logistics cycle in order to make the drugs available at this time and the quantities required by the patients.
For this, the Cuban biotechnology and pharmaceutical industry is planning an investment plan until the year 2030 of more than two billion dollars, which will help expand the production capabilities with high standards.
Source link
